JP2009543579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543579A5 JP2009543579A5 JP2009520824A JP2009520824A JP2009543579A5 JP 2009543579 A5 JP2009543579 A5 JP 2009543579A5 JP 2009520824 A JP2009520824 A JP 2009520824A JP 2009520824 A JP2009520824 A JP 2009520824A JP 2009543579 A5 JP2009543579 A5 JP 2009543579A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- soluble
- wsx
- isolated
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100040066 Interleukin-27 receptor subunit alpha Human genes 0.000 claims 17
- 101710089672 Interleukin-27 receptor subunit alpha Proteins 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 claims 9
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 claims 9
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000009390 immune abnormality Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83221306P | 2006-07-19 | 2006-07-19 | |
| US83745006P | 2006-08-11 | 2006-08-11 | |
| PCT/US2007/016329 WO2008011081A2 (en) | 2006-07-19 | 2007-07-18 | Wsx-1/p28 as a target for anti-inflammatory responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543579A JP2009543579A (ja) | 2009-12-10 |
| JP2009543579A5 true JP2009543579A5 (https=) | 2010-09-02 |
Family
ID=38957359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520824A Pending JP2009543579A (ja) | 2006-07-19 | 2007-07-18 | 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9683026B2 (https=) |
| EP (1) | EP2046809B1 (https=) |
| JP (1) | JP2009543579A (https=) |
| AU (1) | AU2007275654A1 (https=) |
| CA (1) | CA2657934C (https=) |
| DK (1) | DK2046809T3 (https=) |
| ES (1) | ES2612383T3 (https=) |
| MX (1) | MX2009000696A (https=) |
| WO (1) | WO2008011081A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2761885A1 (en) * | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| AU2012205384B2 (en) | 2011-01-14 | 2015-09-10 | Five Prime Therapeutics, Inc. | IL-27 antagonists for treating inflammatory diseases |
| WO2018219959A1 (en) * | 2017-05-29 | 2018-12-06 | Charité Universitätsmedizin Berlin | Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery |
| JP7382625B2 (ja) * | 2019-08-29 | 2023-11-17 | 国立大学法人 鹿児島大学 | 掻痒治療剤 |
| US11859001B2 (en) | 2020-08-05 | 2024-01-02 | Synthekine, Inc. | IL12RB1-Binding molecules and methods of use |
| US20240026014A1 (en) * | 2020-08-05 | 2024-01-25 | Synthekine, Inc. | Compositions and methods related to receptor pairings |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| JP7819178B2 (ja) | 2020-08-05 | 2026-02-24 | シンセカイン インコーポレイテッド | ＩＬ１０Ｒｂ結合分子および使用方法 |
| KR102846963B1 (ko) | 2020-08-05 | 2025-08-18 | 신테카인, 인크. | IL27Rα 결합 분자 및 사용 방법 |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| AU2021322238A1 (en) * | 2020-08-05 | 2023-03-23 | Synthekine, Inc. | Compositions and methods related to IL27 receptor binding |
| WO2022032045A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL10Rα/IL2Rγ SYNTHETIC CYTOKINES |
| KR20230061394A (ko) | 2020-08-05 | 2023-05-08 | 신테카인, 인크. | IL10Ra 결합 분자 및 사용 방법 |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| US12018085B2 (en) | 2020-08-05 | 2024-06-25 | Synthekine, Inc. | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases |
| WO2022031884A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rg binding molecules and methods of use |
| US12291572B2 (en) | 2020-08-05 | 2025-05-06 | Synthekine, Inc. | IL12 receptor synthetic cytokines and methods of use |
| US12012457B1 (en) | 2020-08-05 | 2024-06-18 | Synthekine, Inc. | IL23R binding molecules and methods of use |
| BR112023001723A2 (pt) | 2020-08-05 | 2023-05-02 | Synthekine Inc | Moléculas de ligação à gp130 e métodos de uso |
| CN119757761B (zh) * | 2024-12-16 | 2026-03-06 | 新疆医科大学第一附属医院 | 一种鉴别诊断活动性肺结核的生物标志物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5118791A (en) * | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5665542A (en) * | 1989-11-03 | 1997-09-09 | Research Institute Of Palo Alto Medical Foundation | Toxoplasma gondii P28 gene and methods for its use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7074397B1 (en) * | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| ATE307887T1 (de) | 1996-01-08 | 2005-11-15 | Genentech Inc | Ob-rezeptor und liganden |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| IL122818A0 (en) | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7148330B2 (en) * | 1999-07-30 | 2006-12-12 | Schering Corporation | Binding compounds for IL-27 |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| NZ531141A (en) * | 1999-10-20 | 2005-07-29 | Genentech Inc | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| AU5914201A (en) | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| CA2555421A1 (en) * | 2004-02-17 | 2005-09-01 | Schering Corporation | Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| EP1765400A2 (en) | 2004-06-04 | 2007-03-28 | Genentech, Inc. | Method for treating lupus |
| EP2089712A4 (en) | 2006-11-22 | 2010-09-22 | Life Technologies Corp | BIOMARKERS OF AUTOIMMUNE DISEASES |
-
2007
- 2007-07-18 JP JP2009520824A patent/JP2009543579A/ja active Pending
- 2007-07-18 AU AU2007275654A patent/AU2007275654A1/en not_active Abandoned
- 2007-07-18 MX MX2009000696A patent/MX2009000696A/es active IP Right Grant
- 2007-07-18 CA CA2657934A patent/CA2657934C/en active Active
- 2007-07-18 US US11/880,121 patent/US9683026B2/en active Active
- 2007-07-18 EP EP07836143.3A patent/EP2046809B1/en active Active
- 2007-07-18 ES ES07836143.3T patent/ES2612383T3/es active Active
- 2007-07-18 WO PCT/US2007/016329 patent/WO2008011081A2/en not_active Ceased
- 2007-07-18 DK DK07836143.3T patent/DK2046809T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543579A5 (https=) | ||
| Rasquinha et al. | IL-10 as a Th2 cytokine: differences between mice and humans | |
| Lai et al. | Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases | |
| Bendickova et al. | Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy | |
| Saluja et al. | The role of IL-33 and mast cells in allergy and inflammation | |
| Jin et al. | IL-17 cytokines in immunity and inflammation | |
| Rutz et al. | IL‐22, not simply a Th17 cytokine | |
| Ribeiro-Paes et al. | Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema | |
| Henning et al. | Human umbilical cord blood progenitor cells are attracted to infarcted myocardium and significantly reduce myocardial infarction size | |
| Zhang et al. | Regulatory T cells, a viable target against airway allergic inflammatory responses in asthma | |
| Kim et al. | Innate lymphoid cells in tissue homeostasis and disease pathogenesis | |
| Liu et al. | IFN-α blocks IL-17 production by peripheral blood mononuclear cells in Behçet's disease | |
| Semenzato et al. | Immunology and pathophysiology | |
| Jafarzadeh et al. | Serum levels of interleukin (IL)-27 in patients with ischemic heart disease | |
| Dittel et al. | Ingested (oral) adrenocorticotropic hormone inhibits IL-17 in the central nervous system in the mouse model of multiple sclerosis and experimental autoimmune encephalomyelitis | |
| Li et al. | The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential | |
| Adediran et al. | Prevalence of the metabolic syndrome among Nigerians with type 2 diabetes | |
| CN107812013B (zh) | 一种治疗耐药结核的生物制剂及其制备方法 | |
| O'HEARN et al. | Pulmonary infiltrates after cytokine therapy for stem cell transplantation: massive deposition of eosinophil major basic protein detected by immunohistochemistry | |
| SINGH | SAT-455 TACROLIMUS MAY REGULATE PATHOGENIC TH17 CELLS IN LUPUS NEPHRITIS REFRACTORY PATIENTS | |
| RAI | SAT-454 METFORMIN REDUCES P-GP EXPRESSION AND POTENTIATES ANTI-INFLAMMATORY ACTION OF CORTICOSTEROIDS IN LUPUS NEPHRITIS PATIENTS | |
| Girandon et al. | Treatment of Pulmonary Sarcoidosis Using Allogenic Bone Marrow-Derived Mesenchymal Stem Cell Therapy is Safe: A Case Report | |
| Scheuerman et al. | Mycobacterial disease in a child with surface-expressed non-functional interleukin-12Rbeta1 chains | |
| Bakakos et al. | TCR usage and cytokine expression in peripheral blood and BAL T cells | |
| Goetzl | Changing paradigms in the immunological science of allergy |